These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
67 related articles for article (PubMed ID: 15616602)
1. Antiangiogenic gene therapy of myeloproliferative disease developed in transgenic mice expressing P230 bcr/abl. Miyake K; Inokuchi K; Miyake N; Dan K; Shimada T Gene Ther; 2005 Mar; 12(6):541-5. PubMed ID: 15616602 [TBL] [Abstract][Full Text] [Related]
2. Adeno-associated virus-mediated antiangiogenic gene therapy with thrombospondin-1 type 1 repeats and endostatin. Zhang X; Xu J; Lawler J; Terwilliger E; Parangi S Clin Cancer Res; 2007 Jul; 13(13):3968-76. PubMed ID: 17606731 [TBL] [Abstract][Full Text] [Related]
3. Role of SPA-1 in phenotypes of chronic myelogenous leukemia induced by BCR-ABL-expressing hematopoietic progenitors in a mouse model. Kometani K; Aoki M; Kawamata S; Shinozuka Y; Era T; Taniwaki M; Hattori M; Minato N Cancer Res; 2006 Oct; 66(20):9967-76. PubMed ID: 17047059 [TBL] [Abstract][Full Text] [Related]
4. Stable RNA interference (RNAi) as an option for anti-bcr-abl therapy. Scherr M; Battmer K; Schultheis B; Ganser A; Eder M Gene Ther; 2005 Jan; 12(1):12-21. PubMed ID: 15602589 [TBL] [Abstract][Full Text] [Related]
5. Endostatin gene therapy delivered by Salmonella choleraesuis in murine tumor models. Lee CH; Wu CL; Shiau AL J Gene Med; 2004 Dec; 6(12):1382-93. PubMed ID: 15468191 [TBL] [Abstract][Full Text] [Related]
6. Prostate-restricted replicative adenovirus expressing human endostatin-angiostatin fusion gene exhibiting dramatic antitumor efficacy. Li X; Liu YH; Lee SJ; Gardner TA; Jeng MH; Kao C Clin Cancer Res; 2008 Jan; 14(1):291-9. PubMed ID: 18172281 [TBL] [Abstract][Full Text] [Related]
7. A gene transfer comparative study of HSA-conjugated antiangiogenic factors in a transgenic mouse model of metastatic ocular cancer. Frau E; Magnon C; Opolon P; Connault E; Opolon D; Beermann F; Abitbol M; Perricaudet M; Bouquet C Cancer Gene Ther; 2007 Mar; 14(3):251-61. PubMed ID: 17082795 [TBL] [Abstract][Full Text] [Related]
8. Effects of sustained antiangiogenic therapy in multistage prostate cancer in TRAMP model. Isayeva T; Chanda D; Kallman L; Eltoum IE; Ponnazhagan S Cancer Res; 2007 Jun; 67(12):5789-97. PubMed ID: 17575146 [TBL] [Abstract][Full Text] [Related]
9. Recombinant adeno-associated virus 2-mediated antiangiogenic prevention in a mouse model of intraperitoneal ovarian cancer. Isayeva T; Ren C; Ponnazhagan S Clin Cancer Res; 2005 Feb; 11(3):1342-7. PubMed ID: 15709207 [TBL] [Abstract][Full Text] [Related]
10. Gene therapy for BCR-ABL+ human CML with dual phosphorylation resistant p27Kip1 and stable RNA interference using an EBV vector. Sengupta A; Banerjee D; Chandra S; Banerjee S J Gene Med; 2006 Oct; 8(10):1251-61. PubMed ID: 16952195 [TBL] [Abstract][Full Text] [Related]
11. Myeloproliferative disease in transgenic mice expressing P230 Bcr/Abl: longer disease latency, thrombocytosis, and mild leukocytosis. Inokuchi K; Dan K; Takatori M; Takahuji H; Uchida N; Inami M; Miyake K; Honda H; Hirai H; Shimada T Blood; 2003 Jul; 102(1):320-3. PubMed ID: 12623846 [TBL] [Abstract][Full Text] [Related]
12. Adeno-associated viral vector-mediated expression of endostatin inhibits tumor growth and metastasis in an orthotropic pancreatic cancer model in hamsters. Noro T; Miyake K; Suzuki-Miyake N; Igarashi T; Uchida E; Misawa T; Yamazaki Y; Shimada T Cancer Res; 2004 Oct; 64(20):7486-90. PubMed ID: 15492274 [TBL] [Abstract][Full Text] [Related]
13. Moderate antiangiogenic activity by local, transgenic expression of endostatin in Rip1Tag2 transgenic mice. Schaffhauser B; Veikkola T; Strittmatter K; Antoniadis H; Alitalo K; Christofori G J Leukoc Biol; 2006 Oct; 80(4):669-76. PubMed ID: 16793908 [TBL] [Abstract][Full Text] [Related]
14. [New approach in the diagnosis and monitoring of treatment in chronic myelogenous leukemia]. Matolcsy A Orv Hetil; 2004 Dec; 145(52):2603-9. PubMed ID: 15724695 [TBL] [Abstract][Full Text] [Related]
15. Overexpression/enhanced kinase activity of BCR/ABL and altered expression of Notch1 induced acute leukemia in p210BCR/ABL transgenic mice. Mizuno T; Yamasaki N; Miyazaki K; Tazaki T; Koller R; Oda H; Honda ZI; Ochi M; Wolff L; Honda H Oncogene; 2008 May; 27(24):3465-74. PubMed ID: 18193087 [TBL] [Abstract][Full Text] [Related]
16. Autocrine secretion of osteopontin results in degradation of I kappa B in Bcr-Abl-expressing cells. Vejda S; Piwocka K; McKenna SL; Cotter TG Br J Haematol; 2005 Mar; 128(5):711-21. PubMed ID: 15725094 [TBL] [Abstract][Full Text] [Related]
17. Oncogene inactivation in a mouse model. Tanabe T; Kuwabara T; Warashina M; Tani K; Taira K; Asano S Nature; 2000 Aug; 406(6795):473-4. PubMed ID: 10952298 [No Abstract] [Full Text] [Related]
18. Inhibition of angiogenesis and tumor progression by hydrodynamic cotransfection of angiostatin K1-3, endostatin, and saxatilin genes. Kim KS; Kim DS; Chung KH; Park YS Cancer Gene Ther; 2006 Jun; 13(6):563-71. PubMed ID: 16410825 [TBL] [Abstract][Full Text] [Related]
19. In vivo adenovirus-mediated delivery of a uPA/uPAR antagonist reduces retinal neovascularization in a mouse model of retinopathy. Le Gat L; Gogat K; Bouquet C; Saint-Geniez M; Darland D; Van Den Berghe L; Marchant D; Provost A; Perricaudet M; Menasche M; Abitbol M Gene Ther; 2003 Dec; 10(25):2098-103. PubMed ID: 14595383 [TBL] [Abstract][Full Text] [Related]
20. Out of frame peptides from BCR/ABL alternative splicing are immunogenic in HLA A2.1 transgenic mice. Casnici C; Volpe G; Lattuada D; Crotta K; Kuka M; Panuzzo C; Mastrotto C; Tonon G; Fazio VM; Saglio G; Marelli O Cancer Lett; 2009 Apr; 276(1):61-7. PubMed ID: 19062160 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]